These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17006455)

  • 1. Titrating graft-versus-host disease: is it worth a try?
    Akpek G
    Bone Marrow Transplant; 2006 Nov; 38(10):653-6. PubMed ID: 17006455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow transplantation: new approaches to immunosuppression and management of acute graft-versus-host disease.
    Auletta JJ; Cooke KR
    Curr Opin Pediatr; 2009 Feb; 21(1):30-8. PubMed ID: 19242239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Syngeneic graft-versus-host disease: a report of two cases and literature review.
    Latif T; Pohlman B; Kalaycio M; Sobecks R; Hsi ED; Andresen S; Bolwell BJ
    Bone Marrow Transplant; 2003 Sep; 32(5):535-9. PubMed ID: 12942102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Graft-versus-host disease: emerging concepts in prevention and therapy.
    Dean RM; Bishop MR
    Curr Hematol Rep; 2003 Jul; 2(4):287-94. PubMed ID: 12901325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunosuppressive drugs in the prevention and treatment of GVHD after allogenic bone marrow transplantation].
    Basić-Jukić N; Labar B
    Acta Med Croatica; 2003; 57(2):131-9. PubMed ID: 12879693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there an effective therapy for chronic graft-versus-host disease?
    Schiller G; Gale RP
    Bone Marrow Transplant; 1993 Mar; 11(3):189-92. PubMed ID: 8467281
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of GVHD after blood transfusion.
    Sakuma H; Kikuta A; Suzuki H
    Fukushima J Med Sci; 1993 Dec; 39(2):113-6. PubMed ID: 7927134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary gland involvement in graft-versus-host disease: the underlying mechanism and implicated treatment.
    Nagler RM; Nagler A
    Isr Med Assoc J; 2004 Mar; 6(3):167-72. PubMed ID: 15055275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention and treatment of acute GvHD.
    Messina C; Faraci M; de Fazio V; Dini G; Calò MP; Calore E;
    Bone Marrow Transplant; 2008 Jun; 41 Suppl 2():S65-70. PubMed ID: 18545247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic graft-versus-host disease after allogeneic bone marrow transplantation from an unrelated donor: incidence, risk factors and association with relapse. A report from the Japan Marrow Donor Program.
    Ozawa S; Nakaseko C; Nishimura M; Maruta A; Cho R; Ohwada C; Sakamaki H; Sao H; Mori S; Okamoto S; Miyamura K; Kato S; Kawase T; Morishima Y; Kodera Y;
    Br J Haematol; 2007 Apr; 137(2):142-51. PubMed ID: 17391494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastrointestinal chronic graft-versus-host disease: management options.
    Awan F; Hamadani M
    J Oncol Pharm Pract; 2007 Mar; 13(1):49-51. PubMed ID: 17621568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulating graft-versus-host disease to enhance the graft-versus-leukemia effect.
    Alyea EP
    Best Pract Res Clin Haematol; 2008 Jun; 21(2):239-50. PubMed ID: 18503989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of acute graft-versus-host disease.
    Bacigalupo A
    Br J Haematol; 2007 Apr; 137(2):87-98. PubMed ID: 17391488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literature.
    Kanold J; Merlin E; Halle P; Paillard C; Marabelle A; Rapatel C; Evrard B; Berger C; Stephan JL; Galambrun C; Piguet C; D'Incan M; Bordigoni P; Deméocq F
    Transfusion; 2007 Dec; 47(12):2276-89. PubMed ID: 17764513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine bone marrow derived stromal progenitor cells fail to prevent or treat acute graft-versus-host disease.
    Badillo AT; Peranteau WH; Heaton TE; Quinn C; Flake AW
    Br J Haematol; 2008 Apr; 141(2):224-34. PubMed ID: 18318768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The management and outcome of chronic graft-versus-host disease.
    Fraser CJ; Scott Baker K
    Br J Haematol; 2007 Jul; 138(2):131-45. PubMed ID: 17593020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
    van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
    Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges.
    White JM; Creamer D; du Vivier AW; Pagliuca A; Ho AY; Devereux S; Salisbury JR; Mufti GJ
    Br J Dermatol; 2007 May; 156(5):1032-8. PubMed ID: 17419693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Graft-versus-host disease].
    Svedentsov EP; Sharygin SL; Epifanov NS; Matveev GA
    Klin Med (Mosk); 1993; 71(5):19-23. PubMed ID: 8301977
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.